lowed by radiation or surgery for unstable fractures
that continue to cause neurologic deficits.92–94
The additive combination of new first- and
second-line therapies for metastatic CRPC has
significantly extended survival for patients such
that we are currently rewriting the life span at this
stage of the disease. Many newer agents are in development and emerging, which will likely continue
to improve the outlook for these patients in the
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012.
CA Cancer J Clin 2012;62:10–29.
2. Huggins C, Hodges C. Studies on prostate cancer: the
effect of castration, of estrogen and of androgen injection
on serum phosphatases in metastatic carcinoma of the
prostate. Cancer Res 1941;1:293–7.
3. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically
localized prostate cancer. JAMA 1998;280:969–74.
4. D’Amico AV, Whittington R, Malkowicz SB, et al. Predicting
prostate specific antigen outcome preoperatively in the
prostate specific antigen era. J Urol 2001;166:2185–8.
5. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of PSA progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591–7.
6. Hess KR, Varadhachary GR, Taylor SH, et al. Metastatic
patterns in adenocarcinoma. Cancer 2006;106:1624–33.
7. Wolf JS Jr, Cher M, Dallera M, et al. The use and accuracy of cross-sectional imaging and time needle aspiration
cytology for detection of pelvic lymph node metastases
before radical prostatectomy. J Urol 1995;153:993–9.
8. Briganti A, Passoni N, Ferrari M, et al. When to perform
bone scan in patients with newly diagnosed prostate can-
cer. External validation of the currently available guidelines
and proposal of a novel risk stratification tool. Eur Urol
9. Swerdloff RS, Walsh PC. Testosterone and estradiol suppression of LH and FSH in adult male rats: duration of
castration, duration of treatment and combined treatment.
Acta Endocrinol 1973;73:11–18.
10. Schally AV, Arimura A, Baba Y, et al. Isolation and properties of the FSH and LH-releasing hormone. Biochem
Biophys Res Commun 1971; 43:393-– 9.
11. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and
safety of degarelix: a 12-month, comparative, randomized,
open-label, parallel-group phase III study in patients with
prostate cancer. BJU Int 2008;102:1531–8.
12. Crawford ED, Tombal B, Miller K et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone
agonist and antagonist effect on prostate cancer. J Urol
13. Boccon-Gibod L, van der Meulen E, Persson B-E. An
update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. Ther Adv Urol 2011;3:127–40.
14. Tombal B, Miller K, Boccon-Gibod L, et al. Additional analysis of the secondary end point of biochemicalrecurrence
rate in a Phase 3 trial (CS21) comparing degarelix 80 mg
versus leuprolide in prostate cancer patients segmented
by baseline characteristics. Eur Urol 2010;57:836–42.
15. Schröder FH, Tombal B, Miller K, et al. Changes in alkaline phosphatase levels in patients with prostate cancer
receiving degarelix or leuprolide: results from a 12-month,
comparative, phase III study. BJU Int 2010;106:182–7.
16. Rick FG, Schally AV, Block NL, et al. Mechanisms of synergism between antagonists of growth hormone-releasing
hormone and antagonists of luteinizing hormone-releasing
hormone in shrinking experimental benign prostatic hyperplasia. Prostate 2013;73:873–83.
17. Axcrona K, Aaltomaa S, da Silva CM, et al. Androgen
depriva¬tion therapy for volume reduction, lower urinary
tract symp¬tom relief and quality of life improvement in
patients with prostate cancer: degarelix vs goserelin plus
bicalutamide. BJU Int 2012;110:1721–8.
18. Anderson J, Al-Ali G, Wirth M, et al. Degarelix versus goserelin (+antiandrogen flare protection) in the relief of lower
urinary tract symptoms secondary to prostate cancer:
results from a phase IIIb study (NCT00831233). Urol Int
19. Jacobi GH, Altwein JE, Kurth KH, et al. Treatment of
advanced prostatic cancer with parenteral cyproterone
acetate: a phase III randomized trial. Br J Urol 1980;52:
20. de Voogt HJ, Smith PH, Pavone-Macaluso M, et al. Car-
Test your knowledge of this topic.
Go to www.turner-white.com and select Oncology
from the drop-down menu of specialties.